Naveen's and Raquel's paper on de novo purine metabolism as a vulnerability of p16low cancers is out!

Congratulations to co-first authors Drs. Naveen Kumar Tangudu and Raquel Buj for this very nice study on a metabolic vulnerability in p16low cancers. Using multiple CRISPR screens and omics-based approaches, they identified de novo purine synthesis to be upregulated in p16low cancer cells. They also found that targeting this axis using anti-folates decreased proliferation of these cells both in vitro and in vivo. You can read the full text here: https://aacrjournals.org/cancerrescommun/article/doi/10.1158/2767-9764.CRC-23-0450/743061/De-novo-purine-metabolism-is-a-metabolic